Navigation Links
Generex Announces $1,225,000 Capital Investment
Date:6/17/2013

WORCESTER, Mass. and TORONTO, June 17, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that it entered into a securities purchase agreement with certain institutional investors on June 17, 2013.  The investors have agreed to purchase in a private placement an aggregate of 1,225 shares of the Company's newly designated non-voting Series E 9% Convertible Preferred Stock ("convertible preferred stock") and warrants to purchase up to an aggregate of 100% of the shares of its common stock issuable upon conversion of the convertible preferred stock ("warrants") at the closing.  The convertible preferred stock and warrants will be sold in units, with each unit consisting of one share of convertible preferred stock and a warrant to purchase 100% of the shares of the Company's common stock issuable upon conversion of such share of convertible preferred stock.  Each unit will be sold at a negotiated price of $1,000 for an aggregate purchase price of $1,225,000.  An aggregate of 81,666,666 shares of the Company's common stock will be issuable upon conversion of, or exercise of, the convertible preferred stock and warrants issued at the closing.  In addition, until the one year anniversary of the date of closing, each investor may, in its sole determination, elect to purchase, severally and not jointly with the other investors, in one or more purchases, in the ratio of such investor's original subscription amount to the original aggregate subscription amount of all investors, additional units consisting of convertible preferred stock and warrants at a purchase price of $1,000 per unit with an aggregate subscription amount thereof of up to $1,225,000, which units will be identical to the units of convertible preferred stock and warrants issued in connection with the initial closing.

The convertible
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ASCO Interview of MD Andersons Mittendorf on AE37 Breast Cancer Vaccine Now Available on Generex Websites
2. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
3. Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients
4. Positive Generex Data Underscores Cancer Immunotherapy Forecast Issued by Citi
5. Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine
6. Generex Touts Pipeline Potential of Antigen Express Subsidiary
7. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
8. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
9. Generex Announces Details of Investor Conference Call
10. Generex Addresses Recent Trading Volume in Shares of its Common Stock
11. Generex Announces Results of Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... Brazil and ... and commonly prescribe long-acting beta-agonist (LABA)- and long-acting ... so within current severe cost/coverage constraints. Therefore, new ... expected to launch in these countries—which will considerably ...
(Date:8/21/2014)... MISSION, Kan. , Aug. 21, 2014 /PRNewswire-iReach/ ... Information Trust Alliance (HITRUST) under its Common Security ... ScriptPro,s Enterprise Security and Privacy Manager, "We appreciate ... the level of commitment that this certification signifies. ... compliant." ABOUT THE CSF CERTIFICATION PROCESS: ...
(Date:8/21/2014)... , August 21, 2014 ... BreedIT Ltd., the exclusive worldwide license holder and ... plant breeders and researchers, today is pleased to ... venture with Seach Ltd, a leading Israeli medical ... research and develop new breeds of medical Cannabis ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... 26 Paratek Pharmaceuticals, Inc. today,announced positive Phase ... a first-in-class aminomethylcycline (AMC). The Phase 2 study ... forms of PTK 0796 to,Zyvox(R) in the treatment ... (cSSSIs). Paratek,s trial met its primary safety and,tolerability ...
... affirmed the clinical benefits of,ACTEMRA -, NUTLEY, ... III studies,showed that patients who suffer from the ... significant improvements in signs and,symptoms when treated with ... with methotrexate alone. The final results of,both studies ...
Cached Medicine Technology:Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 2ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 3ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 5ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 6
(Date:8/22/2014)... August 22, 2014 Until now, those with ... crutches or walkers to keep mobile. Thanks to an inventor ... much more effective. , He developed a prototype for the ... injured leg or foot but provide comfort and reduce pain ... different heights, it is also convenient and easy to install ...
(Date:8/22/2014)... a wide range of epigenetic changesalterations in DNA across the ... with Crohn,s disease (CD), reports Inflammatory Bowel Diseases ... Foundation of America (CCFA). The journal is published ... Wolters Kluwer Health . , The study ... of the genome in children with CD, according to Professor ...
(Date:8/22/2014)... lymphoma will be able to better understand their risks ... premature menopause with different treatments. , The findings, set ... Institute , are based on the experience of more ... for the cancer over a period of more than ... with Hodgkin lymphoma who receive certain types of chemotherapy ...
(Date:8/22/2014)... Watertown, MA (PRWEB) August 22, 2014 ... Health (IFNH) at Rutgers, the State University of ... , an innovative children’s media organization, to educate young ... that will build on the strengths of both organizations. ... ChopChop Magazine, a health communications fellowship program, and video ...
(Date:8/22/2014)... Ticket Down is a reliable source for cheap ... Rentschler Field. There has never been a better time to be ... After the strong showing at the 2014 World Cup in Brazil, ... featured in large stadiums around the country. Since the World Cup ... some of the best club teams in the sport played on ...
Breaking Medicine News(10 mins):Health News:Assistive Device for Walking Invented by InventHelp Client (VBL-501) 2Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Scientists map risk of premature menopause after cancer treatment 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:USA vs. Ecuador Tickets: Ticket Down Slashes USA (USMT) vs. Ecuador Tickets at Rentschler Field in East Hartford on Oct. 10th 2Health News:USA vs. Ecuador Tickets: Ticket Down Slashes USA (USMT) vs. Ecuador Tickets at Rentschler Field in East Hartford on Oct. 10th 3
... review investigating the effectiveness of a publicly funded graphic ... been associated with many negative outcomes. The review ... Science , a peer reviewed journal of the Society ... was created in 2005 to reduce methamphetamine use in ...
... or the "Company"), a leading provider of laser vision,correction services under the LasikPlus(R) ... stockholders in response to,recent letters from those stockholders to the Board. , ... Company,s Board of Directors appears,below: , , ... December ...
... Visit Atlantic City , , ATLANTIC CITY, ... who had been wounded in the Iraq conflict and recuperating at Walter ... a visit to Harrah,s Resorts in Atlantic City. , ... women, recovering , from war injuries and wishing for the ...
... N3 Oceanic, Inc. announced the addition of Orosine to ... cardiologist Dr. Jeffrey Shapiro, MD, Assistant Professor of Internal ... Langone Medical Center, who has been giving the formula to ... Dr. Shapiro states, Orosine is the most significant natural product ...
... Precision Optics,Corporation, Inc., (OTC Bulletin Board: POCI) ... the company,s common stock. Stockholders approved,the reverse split ... 2008. The,Board of Directors has determined that the ... Precision Optics Corporation and its stockholders, providing,the benefits ...
... are not being provided in Zimbabwe. The public health system ... Staggering inflation and unemployment have resulted in shortages of food ... of cholera, which is being spread by a shortage of ... date, the outbreak has claimed over 600 lives. , ...
Cached Medicine News:Health News:Success of anti-meth ads questioned by study 2Health News:Success of anti-meth ads questioned by study 3Health News:LCA-Vision Board of Directors Responds to Recent Letters from Stockholder Group 2Health News:LCA-Vision Board of Directors Responds to Recent Letters from Stockholder Group 3Health News:LCA-Vision Board of Directors Responds to Recent Letters from Stockholder Group 4Health News:Wounded Warriors to be Holiday Guests of Harrah's Entertainment 2Health News:Res-Q Gains Rights To Market Orosine - a Breakthrough, Patented, Natural Heart Supplement That Cardiologists Are Calling the 'Ultimate Cardio Protection' Against Heart Attacks, Strokes and Heart Failure. 2Health News:Precision Optics Corporation to Effect Reverse Split and Ticker Symbol Change 2
55 DSL's new collection of optical frames has established a strong personality and developed,superficial retro concepts with contemporary styles and strong impacting colours....
... and highly sought-after, the ... collection of sunglasses and ... the very latest men's ... timeless sources of inspiration ...
... Extended Ablation laser enables the physician to provide ... results and no downtime., The new Whisper NG ... an extra long pulse width to achieve "Extended ... over 3-5 days, and occurs simultaneously with the ...
... the art software package designed to assist in ... by a lens manufacturer with years of experience ... is designed to help you run your lab ... the software dictates., ,Designed specifically for integrated retail ...
Medicine Products: